A Randomized, Double Blind, Placebo Controlled Study to Explore the Antidepressant Properties of P38a Kinase Inhibitor GW856553X 15mg Compared to PBO in Subjects With Major Depressive Disorder Exhibiting Symptoms of Loss of Energy and Interest and Psychomotor Retardation, for a Six Week Treatment Period
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Losmapimod (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2008 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Dec 2007 to Sep 2007 as reported by ClinicalTrials.gov.